Medicago investing $32M in new production facility; SciClone shares plunge on China probe; Zurex opens shop in Madison;

 @FierceBiotech: Mayo Clinic to launch center for social media. Report | Follow @FierceBiotech

 @JohnCFierce: It's rare to see a Phase III drug with the kind of compelling, clean profile that telaprevir has. | Follow @JohnCFierce

> The vaccine developer Medicago, which is making vaccines from tobacco plants, is investing $32 million in a new production facility in Research Triangle Park. The project will lead to the creation of 85 new jobs. Report

> Shares of SciClone Pharmaceuticals plunged after the company said that the feds are investigating its business activities in China. Article

> The UK's Tissue Regenix has received its first approval, gaining the European CE mark for a new patch designed to promote tissue repair. The dCELL vascular patch uses human and animal cells to create a scaffold for tissue regeneration. And the company says it is now pursuing an FDA approval as well. Tissue Regenix went public through a reverse merger in June. It makes the patch, which is designed to avert the use of anti-rejection therapies, in York. Story

> The startup Zurex Pharma, which is developing antimicrobial products, set up shop in Madison, WI. Item

> Nabi has earned an $8 million milestone from its sale of PentaStaph (Pentavalent S. aureus Vaccine) and related assets to GSK. Nabi release

> Syndax Pharmaceuticals has raised $6 million from 12 investors. Story

> AVI BioPharma revealed that it paid $2.6 million to its ex-CEO, Leslie Hudson, huirting its second quarter results. Hudson left the company in April and the CFO is serving as interim CEO. News

And Finally... Fresh research shows that a big waist is a big risk. Report

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.